T. Rowe Price (NASDAQ: DYN) lists 26,578,437 shares, a 16.2% stake
Rhea-AI Filing Summary
Dyne Therapeutics reports a Schedule 13G/A from T. Rowe Price Investment Management showing beneficial ownership of 26,578,437 shares of common stock, representing 16.2% of the class.
The filing shows sole voting power for 26,223,470 shares and sole dispositive power for 26,578,437. The filing includes a statement denying beneficial ownership by T. Rowe Price Investment Management. The form is signed by Ellen York on 03/06/2026.
Positive
- None.
Negative
- None.
Insights
T. Rowe Price reports a substantial passive stake in Dyne Therapeutics at
The filing lists 26,578,437 shares beneficially owned with 26,223,470 shares of sole voting power as of the amendment date. The filer also includes an explicit denial of beneficial ownership in the text.
Institutional filings like this commonly reflect investment management positions; the exact economic interest attribution is subject to the filer’s reservation language. Subsequent filings or disclosures could clarify voting or investment authority.
FAQ
What does the T. Rowe Price 13G/A filing for DYN mean?
How many Dyne shares does T. Rowe Price have voting power over?
Does the filing prove T. Rowe Price is the beneficial owner of DYN shares?
When was the Schedule 13G/A signed and filed for DYN?